NeurAxon Inc.

Presenter: Lawrence Bloch, CEO and President

Company Information

Company Type: Pharmaceuticals

Development Stage: Private

Company Profile

NeurAxon is the leader in discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Company Strategy

To develop product candidates through Phase 2 proof of concept and then partner with the best collaborator for pivotal studies, registration and commercialization.

Intellectual Property

Internally generated compositon of matter as well as method of use patents on novel, first-in-class, single and dual-action NCE, selective inhibitors of nNOS.

Programs

NXN-188 (nNOS/5HT): Acute Migraine [Phase 2]
NXN-462 (nNOS): Neuropathic Pain [Phase 1]
nNOS/iNOS: Inflammatory Pain [Preclinical]
nNOS/Opioid: Severe Pain [Preclinical]
nNOS/NET: Migraine Prophylaxis, Depression/Anxiety [Preclinical]

Investors

Ventures West
CTI Life Sciences Fund
Genesys Capital Partners
BDC Venture Capital
H.I.G. Ventures
Delphi Ventures
OrbiMed Advisors
NeuroVentures

Management Team

Lawrence Bloch, MD, JD, Chief Executive Officer
John S. Andrews, PhD, Chief Scientific Officer
Robert A. Medve, MD, Chief Medical Officer
Tom Lategan DPhil, Vice President of Regulatory Affairs
Suman Rakhit, PhD, Executive VP of Chemistry
Shawn Maddaford, PhD, Vice President of Discovery Chemistry

Presenter Bio

Dr. Bloch has served as NeurAxon, Inc.'s Chief Executive Officer since 2007 raising $40.75 million in equity in NeurAxon's Series B financing. From 2004 to 2006 he served as Chief Business Officer and Chief Financial Officer of NitroMed, Inc., raising $150 million in equity and $20 million in debt to support company growth from 40 to 300 employees including an exclusively dedicated contract sales force for the commercial launch of BiDil. From 2000 to 2004 he served as Chief Financial Officer, and from 1999 to 2002 as Vice President of Business Development, of Applied Molecular Evolution, Inc., leading AME's $101.6 million IPO to support company growth from 18 to 135 employees and AME's $420 million merger with Eli Lilly and Company. Dr. Bloch earned a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

Contact

NeurAxon Inc.
480 University Ave., Suite 900
Toronto
ON, Canada
M5G 1V2

ph: 416-673-6697
fx: 416-595-8249

www.neuraxon.com
lbloch@neuraxon.com